Fri.Apr 26, 2024

Remove fda-labelling
article thumbnail

FDA Approves Label Update for Biktarvy as Treatment of HIV in Pregnant Adults

Pharmacy Times

The approval is based on data from Study 5310, evaluating the pharmacokinetics, safety, and efficacy of Biktarvy (Gilead Sciences Inc) in pregnant individuals.

Labelling 123
article thumbnail

FDA Approves Label Update for Gilead’s Biktarvy to Include Pregnant Adults With HIV

PharmExec

Approval update comes as a result of findings from Study 5310, which addressed Biktarvy’s pharmacokinetics, safety, and efficacy during pregnancy and postpartum periods in patients with HIV.